This article is more than 5 years old. Information may no longer be current.

EntreMed, NEI to jointly study retinal angiogenesis

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

ROCKVILLE, Md. — EntreMed Inc. (NASDAQ: ENMD), in a joint cooperative research and development agreement with the National Eye Institute, will study the role that its drug Panzem (2-methoxyestradiol) might play in treating the retinal angiogenesis that leads to age-related macular degeneration.

Under the terms of the agreement, EntreMed scientists will formalize ongoing collaborations with the NEI designed to test the potential efficacy of a sustained-release ocular implant of Panzem in a model of growth-factor induced angiogenesis in the eyes of mice. To date, preclinical studies have shown that intraocular Panzem given in a slow-release pellet inhibits the proliferation of growth factor-induced blood vessels in the retinas of mice.

"EntreMed is pleased to begin a joint venture with the NEI to study Panzem," said Dr. John W. Holaday, EntreMed's chairman and chief executive officer. "Panzem was discovered by Dr. Robert D'Amato, a world-class ophthalmologist and scientist working with Dr. Judah Folkman at Children's Hospital in Boston. Although to date we have emphasized its use in the treatment of cancers, early data obtained in collaboration with scientists at the NEI have shown promise in arresting the growth of new blood vessels in the eye."